Post-acute Sequelae of SARS-COV-2 Infection
Conditions
Keywords
long-COVID, Apollo
Brief summary
The purpose of this study is to examine how Apollo wearable use impacts symptoms and quality of life following long COVID.
Detailed description
Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as long-COVID, is a syndrome that describes the persistence of symptoms or other sequelae weeks or months after initial SARS-CoV-2 infection. Limited evidence exists for effective treatments for this syndrome. In this observational study, the investigators will examine the effects of Apollo wearable use on symptoms and quality of life related to long-COVID. The Apollo Neuroscience System (combined wearable and mobile application) offers a convenient, non-invasive, non-habit-forming wearable solution to improve performance and recovery under stress in children and adults. Our sample will be composed of new purchasers of Apollo or previous users of Apollo who haven't used Apollo in the preceding 14 days who are currently experiencing symptoms related to long-COVID according to PASC (self report). Clinically validated survey tools will be administered upon enrollment in the study to assess baseline symptoms and quality of life. Once consented and enrolled in the study, participants will complete 7 monthly surveys for 6 months. Usage data from subjects' use of the wearable is also saved on the wearable directly and periodically uploaded to Apollo Neuroscience's secure and confidential database to be stored for analysis. Participants will first complete a screener survey to assess eligibility to participate. Demographic information and medication, substance, and treatment usage will also be collected. Participants may choose to provide biometric data at their discretion for purposes of comparison at least 8 weeks before the study period, during the study period for 6 months, and at most 8 weeks after the study period. With regular Apollo use, the investigators expect to see an improvement in the physical, cognitive, and psychological symptoms associated with PASC. Initial analysis will compare subjects' baseline scores before Apollo use to scores during/after Apollo and the scores of subjects who used Apollo according to the study protocol and the scores of those who did not. Information gained from this study will help evaluate the use of Apollo as a potential non-invasive and accessible solution to aid in reducing long-COVID symptoms.
Interventions
None listed
Sponsors
Apollo Neuroscience, Inc.
The Board of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* New purchasers of Apollo who haven't started using their Apollo device or previous users of Apollo who haven't used Apollo in the preceding 14 days. * Age 18 years or over * Currently experiencing symptoms related to long-COVID according to PASC (self report). * Must be experiencing PASC symptoms in at least one of the following domains: Respiratory-related symptoms Fatigue-related symptoms Neurologic-related symptoms Psychiatric-related symptoms Sleep-related symptoms Change in quality of life/functional status
Exclusion criteria
* Inability to use or access a compatible Android or iOS smartphone * Are unable to complete consent and questionnaires written in English * Current resident of a European Union (EU) country
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Post-Covid-19 Functional Status Scale (PCFS) | Monthly for 6 months | Post-Covid-19 Functional Status Scale (PCFS) will be used to assess participants' functional recovery following a COVID-19 diagnosis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Modified Medical Research Council (mMRC) Dyspnea Scale | Monthly for 6 months | The Modified Medical Research Council (mMRC) Dyspnea Scale will be used to assess dyspnea (labored breathing). |
| EuroQol-5D-5L (EQ-5D) | Monthly for 6 months | The EuroQol-5D-5L (EQ-5D) will measure health in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. |
| Neurobehavioral Symptom Inventory (NSI) | Monthly for 6 months | The Neurobehavioral Symptom Inventory (NSI) will be used to assess neurobehavioral symptoms. |
| Fatigue Severity Scale (FSS) | Monthly for 6 months | The Fatigue Severity Scale (FSS) will be used to measure the severity of fatigue symptoms. |
| Pittsburgh Sleep Quality Index (PSQI) | Monthly for 6 months | The Pittsburgh Sleep Quality Index (PSQI) will be used to quantify sleep quality and disturbances over a month interval at a time. |
Countries
United States
Contacts
Primary ContactBelinda Tan, MD, PhD
Backup ContactEma Perez, BS
Outcome results
None listed